Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotevtamab - Alethia BioTherapeutics/International Biotechnology Center Generium

Next Previous
Drug Profile

Sotevtamab - Alethia BioTherapeutics/International Biotechnology Center Generium

Alternative Names: 16B5; AB-16B5; AB-sCLU mAB; Anti-clusterin monoclonal antibody - Alethia Biotherapeutics

Latest Information Update: 09 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Research Council Biotechnology Research Institute
  • Developer Alethia BioTherapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Clusterin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 09 Sep 2026 Alethia Biotherapeutics completes the phase II EGIA-003 trial in in Colorectal cancer (Combination therapy, Metastatic disease, Neoadjuvant therapy, Late-stage disease) in Canada (IV) prior to September 2026 (NCT06225843)
  • 31 May 2024 Efficacy and adverse events data from the phase II EGIA-002 trial in Non-small cell lung cancer presented results at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 15 Feb 2024 Phase-II clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Neoadjuvant therapy, Late-stage disease) in Canada (IV) (NCT06225843)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top